Immunomodulatory effects of atorvastatin on MRL/lpr mice

Kiriakidou M, Ching C. Systemic lupus erythematosus. J Ann Intern Med. 2020;172:ITC81–96.

Article  Google Scholar 

Tsokos GC. Systemic lupus erythematosus. N Engl J Med. 2011;365:2110–21.

Article  CAS  PubMed  Google Scholar 

Barber MRW, Drenkard C, Falasinnu T, Hoi A, Mak A, Kow NY, et al. Global epidemiology of systemic lupus erythematosus. Nat Rev Rheumatol. 2021;17:515–32.

Article  PubMed  PubMed Central  Google Scholar 

Greenwood J, Steinman L, Zamvil SS. Statin therapy and autoimmune disease: from protein prenylation to immunomodulation. Nat Rev Immunol. 2006;6:358–70.

Article  CAS  PubMed  Google Scholar 

Cholesterol Treatment Trialists’ Collaboration, Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet (London, England). 2010;376:1670–81.

Article  Google Scholar 

Mollazadeh H, Tavana E, Fanni G, Bo S, Banach M, Pirro M, et al. Effects of statins on mitochondrial pathways. J Cachexia Sarcopenia Muscle. 2021;12:237–51.

Article  PubMed  PubMed Central  Google Scholar 

Greenwood J, Steinman L, Zamvil SS. Statin therapy and autoimmune disease: from protein prenylation to immunomodulation. Nat Rev Immunol. 2006;6:358–70.

Article  CAS  PubMed  Google Scholar 

Fasano S, Margiotta DP, Navarini L, Pierro L, Pantano I, Riccardi A, et al. Primary prevention of cardiovascular disease in patients with systemic lupus erythematosus: case series and literature review. Lupus. 2017;26:1463–72.

Article  CAS  PubMed  Google Scholar 

Li GM, Zhao J, Li B, Zhang XF, Ma JX, Ma XL, et al. The anti-inflammatory effects of statins on patients with rheumatoid arthritis: a systemic review and meta-analysis of 15 randomized controlled trials. Autoimmun Rev. 2018;17:215–25.

Article  CAS  PubMed  Google Scholar 

Youssef S, Stüve O, Patarroyo JC, Ruiz PJ, Radosevich JL, Hur EM, et al. The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature. 2002;420:78–84.

Article  CAS  PubMed  Google Scholar 

Zeiser R. Immune modulatory effects of statins. Immunology. 2018;154:69–75.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Watanabe T, Oku K, Amengual O, Hisada R, Ohmura K, Nakagawa I, et al. Effects of statins on thrombosis development in patients with systemic lupus erythematosus and antiphospholipid antibodies. Lupus. 2018;27:225–34.

Article  CAS  PubMed  Google Scholar 

Artola RT, Mihos CG, Santana O. Effects of statin therapy in patients with systemic lupus erythematosus. South Med J. 2016;109:705–11.

CAS  PubMed  Google Scholar 

Kwak B, Mulhaupt F, Myit S, Mach F. Statins as a newly recognized type of immunomodulator. Nat Med. 2000;6:1399–402.

Article  CAS  PubMed  Google Scholar 

Lawman S, Mauri C, Jury E, Cook H, Ehrenstein M. Atorvastatin inhibits autoreactive B cell activation and delays lupus development in New Zealand black/white F1 mice. J Immunol. 2004;173:7641–6.

Article  CAS  PubMed  Google Scholar 

Graham KL, Lee LY, Higgins JP, Steinman L, Utz PJ, Ho PP. Failure of oral atorvastatin to modulate a murine model of systemic lupus erythematosus. Arthritis Rheum. 2008;58:2098–104.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Theofilopoulos AN, Dixon FJ. Etiopathogenesis of murine SLE. Immunol Rev. 1981;55:179–216.

Article  CAS  PubMed  Google Scholar 

Moore E, Putterman C. Are lupus animal models useful for understanding and developing new therapies for human SLE? J Autoimmun. 2020;112:102490.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Laing ST. High-intensity statins: guideline expectations and clinical application. JAMA. 2017;317:2543–4.

Article  PubMed  Google Scholar 

Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;139:e1082–143.

PubMed  Google Scholar 

Tao X, Fan F, Hoffmann V, Longo NS, Lipsky PE. Therapeutic impact of the ethyl acetate extract of Tripterygium wilfordii Hook F on nephritis in NZB/W F1 mice. Arthritis Res Ther. 2006;8:R24.

Article  PubMed  PubMed Central  Google Scholar 

Pisetsky DS. Evolving story of autoantibodies in systemic lupus erythematosus. J Autoimmun. 2020;110:102356.

Article  CAS  PubMed  Google Scholar 

Wang X, Xia Y. Anti-double stranded DNA antibodies: origin, pathogenicity, and targeted therapies. Front Immunol. 2019;10:1667.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kim AHJ, Strand V, Sen DP, Fu Q, Mathis NL, Schmidt MJ, et al. Association of blood concentrations of complement split product iC3b and serum C3 with systemic lupus erythematosus disease activity. Arthritis Rheumatol (Hoboken, NJ). 2019;71:420–30.

Article  CAS  Google Scholar 

Lawman S, Mauri C, Jury EC, Cook HT, Ehrenstein MR. Atorvastatin inhibits autoreactive B cell activation and delays lupus development in New Zealand black/white F1 mice. J Immunol (Baltimore, Md: 1950). 2004;173:7641–6.

Article  CAS  Google Scholar 

Sahebkar A, Rathouska J, Derosa G, Maffioli P, Nachtigal P. Statin impact on disease activity and C-reactive protein concentrations in systemic lupus erythematosus patients: a systematic review and meta-analysis of controlled trials. Autoimmun Rev. 2016;15:344–53.

Article  CAS  PubMed  Google Scholar 

Ho A, Barr SG, Magder LS, Petri M. A decrease in complement is associated with increased renal and hematologic activity in patients with systemic lupus erythematosus. Arthritis Rheum. 2001;44:2350–7.

Article  CAS  PubMed  Google Scholar 

Thurman JM. Complement in kidney disease: core curriculum 2015. Am J Kidney Dis. 2015;65:156–68.

Article  PubMed  Google Scholar 

Lee H-Y, Ahn J, Park J, Kyung Kang C, Won S-H, Wook Kim D, et al. Beneficial effect of statins in COVID-19-related outcomes-brief report: a national population-based cohort study. Arterioscler Thromb Vasc Biol. 2021;41:e175–82.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dotan A, Muller S, Kanduc D, David P, Halpert G, Shoenfeld Y. The SARS-CoV-2 as an instrumental trigger of autoimmunity. Autoimmun Rev. 2021;20:102792.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bianchi S, Bigazzi R, Caiazza A, Campese VM. A controlled, prospective study of the effects of atorvastatin on proteinuria and progression of kidney disease. Am J Kidney Dis. 2003;41:565–70.

Article  CAS  PubMed  Google Scholar 

McCarey DW, McInnes IB, Madhok R, Hampson R, Scherbakov O, Ford I, et al. Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomised placebo-controlled trial. Lancet (London, England). 2004;363:2015–21.

Article  CAS  PubMed  Google Scholar 

Abud-Mendoza C, de la Fuente H, Cuevas-Orta E, Baranda L, Cruz-Rizo J, González-Amaro R. Therapy with statins in patients with refractory rheumatic diseases: a preliminary study. Lupus. 2003;12:607–11.

Article  CAS  PubMed  Google Scholar 

留言 (0)

沒有登入
gif